Trends in Dry Eye Disease Management Worldwide

Código QR

Trends in Dry Eye Disease Management Worldwide

Mohamed Mostafa Hantera Department of Ophthalmology, Umm AL Qura University, Jeddah, Saudi ArabiaCorrespondence: Mohamed Mostafa HanteraMedical Reference Center, King Road After Hiraa Crossing, Jeddah, Saudi ArabiaTel +966552553322Email Mohamedhantera30@gmail.comAbstract: Dry eye disease (DED) is a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Hantera MM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	dry eye disease etiology prevalence therapy survey Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/e01240631585461e82e663607e107525
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A
por: Jariyakosol S, et al.
Publicado: (2021)

A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease
por: Jerkins G, et al.
Publicado: (2020)

Efficacy and Safety of Phospholipid Nanoemulsion-Based Ocular Lubricant for the Management of Various Subtypes of Dry Eye Disease: A Phase IV, Multicenter Trial
por: Yeu E, et al.
Publicado: (2020)

Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
por: de Oliveira RC, et al.
Publicado: (2019)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
por: Deveney T, et al.
Publicado: (2018)

The Prevalence and Incidence of Dry Eye Disease Among Patients Using Continuous Positive Airway Pressure or Other Nasal Mask Therapy Devices to Treat Sleep Apnea
por: Matossian C, et al.
Publicado: (2020)

Comparison of Autonomous AS-OCT Deep Learning Algorithm and Clinical Dry Eye Tests in Diagnosis of Dry Eye Disease
por: Chase C, et al.
Publicado: (2021)

Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
por: Shen Lee B, et al.
Publicado: (2020)

Effect of topical 3% diquafosol sodium on eyes with dry eye disease and meibomian gland dysfunction
por: Amano S, et al.
Publicado: (2017)

Patient-reported severity of dry eye and quality of life in diabetes
por: Yazdani-Ibn-Taz MK, et al.
Publicado: (2019)

Making the diagnosis of Sjögren’s syndrome in patients with dry eye
por: Beckman KA, et al.
Publicado: (2015)

Possible association between subtypes of dry eye disease and seasonal variation
por: Ayaki M, et al.
Publicado: (2017)

Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity
por: Pepose JS, et al.
Publicado: (2019)

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
por: Tauber J, et al.
Publicado: (2018)

Symptom Relief Following a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion in Patients with Dry Eye Disease: A Phase IV, Multicenter Trial
por: Silverstein S, et al.
Publicado: (2020)

Exercise program improved subjective dry eye symptoms for office workers
por: Sano K, et al.
Publicado: (2018)

Effects of 3% diquafosol sodium ophthalmic solution on higher-order aberrations in patients diagnosed with dry eye after cataract surgery
por: Inoue Y, et al.
Publicado: (2016)

Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease
por: White DE, et al.
Publicado: (2020)

Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study
por: McDonald MB, et al.
Publicado: (2018)

A Decade of Effective Dry Eye Disease Management with Systane Ultra (Polyethylene Glycol/Propylene Glycol with Hydroxypropyl Guar) Lubricant Eye Drops
por: Srinivasan S, et al.
Publicado: (2021)

Characterization of the serological biomarkers associated with Sjögren’s syndrome in patients with recalcitrant dry eye disease
por: Matossian C, et al.
Publicado: (2016)

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature
por: Rhee MK, et al.
Publicado: (2017)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
por: Matossian C, et al.
Publicado: (2021)

Corneal thickness in dry eyes in an Iraqi population
por: Ali NM, et al.
Publicado: (2017)

Dry eye syndrome: developments and lifitegrast in perspective
por: Lollett IV, et al.
Publicado: (2018)

Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease
por: Yeu E, et al.
Publicado: (2019)

Intense pulsed light for evaporative dry eye disease
por: Dell SJ
Publicado: (2017)

Combination of hyaluronic acid, carmellose, and osmoprotectants for the treatment of dry eye disease
por: Mateo Orobia AJ, et al.
Publicado: (2018)

A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
por: McMullin D, et al.
Publicado: (2021)

Efficacy of polyethylene glycol–propylene glycol-based lubricant eye drops in reducing squamous metaplasia in patients with dry eye disease
por: Aguilar A, et al.
Publicado: (2018)

Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease
por: White DE, et al.
Publicado: (2020)

Effect of Refresh Plus® preservative-free lubricant eyedrops on tear ferning patterns in dry eye and normal eye subjects
por: Alanazi SA, et al.
Publicado: (2019)

The use of preservatives in dry eye drops
por: Walsh K, et al.
Publicado: (2019)

Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye
por: Sambursky R
Publicado: (2016)

Efficacy and safety of glycyrrhizin 2.5% eye drops in the treatment of moderate dry eye disease: results from a prospective, open-label pilot study
por: Burillon C, et al.
Publicado: (2018)

Ocular Surface Changes in Patients with Thyroid Eye Disease: An Observational Clinical Study
por: Allam IY, et al.
Publicado: (2021)

Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease
por: Semba CP, et al.
Publicado: (2016)

Frequency and risk factors associated with dry eye in patients attending a tertiary care ophthalmology center in Mexico City
por: Martinez JD, et al.
Publicado: (2016)

TearCare® system extension study: evaluation of the safety, effectiveness, and durability through 12 months of a second TearCare® treatment on subjects with dry eye disease
por: Badawi D
Publicado: (2019)

A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease
por: Taylor M, et al.
Publicado: (2019)